cc 1

CC214-1 is an mTOR inhibitor with potential anticancer activity, inhibits protein translation, and induces autophagy. CC214-1 is an in vitro tool compound for exploring the biology of mTOR kinases and can be used to study myeloma.

MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugate (ADC) utilizing a protein-degrading agent (protac molecular glue, etc.).

CC-885-CH2-PEG1-NH-CH3 is a neoDegrader compound employed for the production of Antibody neoDegrader Conjugate (AnDC) during synthesis.

Dicyclanil is an insect growth regulator with a chemical structure similar to that of cyclopromazine.

C 021 dihydrochloride is a potent CCR4 antagonist. C-021 (4-Quinazolinamine, 2-[1,4'-bipiperidin]-1'-yl-N-cycloheptyl-6,7-dimethoxy-) dihydrochloride potently inhibits functional chemotaxis in humans and mice with IC50s of 140 nM and 39 nM, respectively. It effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor (IC50: 18 nM).

Pulrodemstat (CC-90011) is a highly potent and selective inhibitor of lysine specific demethylase-1 (LSD1). It exhibits a reversible mode of action and can be administered orally. With an impressive IC50 of 0.25 nM, Pulrodemstat effectively suppresses the enzymatic activity of LSD1. Notably, it demonstrates minimal inhibition against LSD2, MOA-A, and MAO-B enzymes. Moreover, Pulrodemstat possesses remarkable anticancer properties, promoting differentiation in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells.

Minretumomab (CC-49), a murine monoclonal antibody targeting TAG-72 (tumor-associated glycoprotein 72), serves a role in cancer and immunity research [1] [2].

CC-3060 is a potent Cereblon modulator that facilitates the degradation of ZBTB16, exhibiting a DC50 of 0.47 nM in HT-1080 cells. It orchestrates ZBTB16 degradation by targeting discrete structural degrons within various zinc finger domains [1].

Anzurstobart (CC-95251; BMS-986351), a fully human monoclonal anti-SIRPα antibody with high affinity, inhibits CD47-SIRPα interaction. It potentiates macrophage-mediated phagocytosis of DLBCL cell lines in co-culture assays with Rituximab and shows promise in solid and hematologic malignancy research [1].

CCR2-RA-[R] is a C-C chemokine receptor type 2 (CCR2) allosteric antagonist (IC50: 103 nM).

gp120-IN-1 (compound 4e) is a potent HIV-1 gp120 inhibitor with an CC 50 of 100.90 μM and IC 50 of 2.2 μM. gp120-IN-1 inhibitis gp120-mediated virus enter into cells. gp120-IN-1 has anti-HIV-1 activity. gp120-IN-1 has dose-dependent cytotoxicity in SUP-T1 cells [1].

Influenza virus-IN-2 (compound 19) has anti-influenza A virus activities that is a potent inhibitor of influenza virus with an CC 50 of 150.85 μM and EC 50 of 2.58 μM. Influenza virus-IN-2 concentration-dependently inhibits the PAN endonuclease with EC 50 of 489.39 nM [1].

vMIP-II (1-21), a CXCR4 antagonist, exhibits broad-spectrum interaction with both CC and CXC chemokine receptors, specifically binding to CXCR4. It competes for CXCR4 binding of 125I-SDF-1R with an IC 50 value of 190 nM [1].

Pulrodemstat benzenesulfonate (CC-90011 benzenesulfonate) is a potent and orally active inhibitor of lysine specific demethylase-1 (LSD1) with anticancer activity.

Lenalidomide hydrochloride (CC-5013 hydrochloride), a Thalidomide derivative, functions as molecular glue and serves as an orally active immunomodulator. As a ligand for the ubiquitin E3 ligase cereblon (CRBN), it facilitates the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase. Specifically, Lenalidomide hydrochloride inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and promotes IL-2 release from T cells [1] [2].

AP-22408 is an inhibitor of SRC tyrosine kinase.

CC-90003 is a selective inhibitor of ERK 1 2. It has antitumor activity.

CCR4 Antagonist 4 (Compound 22) is a potent and selective antagonist of the CC chemokine receptor-4 (CCR4), displaying an IC50 value of 0.02 μM. It also inhibits MDC-mediated chemotaxis and Ca2+ mobilization, with IC50 values of 0.007 μM and 0.003 μM, respectively. This compound is utilized in research on allergic inflammation [1].

Antiparasitic agent-4 (compound 4q) exhibits high antiparasitic activity with IC50 of 8.51 μM for Leishmania infantum (L. infantum) and IC50 of 2.20 μM for Trypanosoma cruzi ( T. cruzi ). Antiparasitic agent-4 is also cytotoxic against HepG2 with CC 50 of 18.97 μM[1].

CC-3052 is a water-soluble, highly stable thalidomide analogue that is an effective inhibitor of HIV-1 expression and activation-induced TNF-α production. CC-3052 also inhibited PHA-induced and rTNF-α induced TNF-α transcription in PBMC, as well as TNF-α

gp120-IN-2 (compound 4i) exhibits anti-HIV-1 activity which is a potent inhibitor of HIV-1 gp120 with an IC 50 of 7.5 μM and CC 50 of 112.93 μM. gp120-IN-2 dose-dependently shows cytotoxicity in SUP-T1 cells [1].

CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC50=4440 nM). CC-90005 can inhibit T cell activation by IL-2 expression[1]. CC-90005 shows the exquisite selectivity of CC-90005, with IC50s for all other family members of >3 μM[1].CC-90005 is a moderate inhibitor of both CYP2C9 (IC50=8 μM) and CYP2C19 (IC50=5.9 μM) in human liver microsomes[1].CC-90005 inhibits IL-2 expression in LRS_WBC human PBMCs, with an IC50 of 0.15 μM[1].CC-90005 (1-10 μM; 24 h) inhibits T cell proliferation in PBMCs by 51% at 1 μM and 88% at 3 μM[1]. CC-90005 (3-30 mg/kg; p.o. twice daily for 4 days) significantly reduces the popliteal lymph node (PLN) size in a model of chronic T cell activation[1].CC-90005 (100 mg/kg; a single p.o.) significantly inhibits plasma and spleen IL-2 release by 51 and 54%, respectively[1].CC-90005 exhibits reasonable oral bioavailability (66 and 46%) and Cmax (1.18 and 1.2 μM) following oral administration (10 and 3 mg/kg) in rat and dog, respectively[1].CC-90005 exhibits the mean residence time (0.52 and 2.0 h), CL (69.1 and 20.5 mL/min/kg) and Vss (2.11 and 2.44 L/kg) following intravenous administration (2 and 1 mg/kg) in rat and dog, respectively[1]. [1]. Papa P, et, al. Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005. J Med Chem. 2021 Aug 26;64(16):11886-11903.

KRH-1636 is an orally active, selective and extremely potent CXC chemokine receptor 4 antagonist. KRH-1636 exhibits a potent and selective anti-HIV-1 activity. KRH-1636 efficiently blocked replication of various T cell line-tropic (X4) HIV type 1 (HIV-1) in MT-4 cells and peripheral blood mononuclear cells through the inhibition of viral entry and membrane fusion via the CXC chemokine receptor (CXCR)4 coreceptor but not via CC chemokine receptor 5. KRH-1636 also inhibits binding of the CXC chemokine, stromal cell-derived factor 1alpha, to CXCR4 specifically and subsequent signal transduction. KRH-1636 prevented monoclonal antibodies from binding to CXCR4 without down-modulation of the coreceptor. KRH-1636 seems to be a promising agent for the treatment of HIV-1 infection.

BMS CCR2 22 is a potent and selective antagonist of CCR2 with calcium flux IC50 of 18 nM, chemotaxis IC50 of 1 nM, and binding IC50 of 5.1 nM.

CC-90002, a humanized anti-CD47 monoclonal antibody (mAb), demonstrates high affinity for CD47, characterized by a subnanomolar dissociation constant (K d). It is utilized in the research of hematologic malignancies and solid tumors [1] [2].

CCR2 antagonist 4 (Teijin compound 1) is a potent and specific antagonist of CCR2(IC50s of 180 nM), and potently inhibits MCP-1-induced chemotaxis(IC50 of 24 nM).

FtsZ-IN-4, an orally active inhibitor of FtsZ (filamenting temperature-sensitive mutant Z), demonstrates remarkable antibacterial activity and favorable pharmaceutical properties. With low cytotoxicity (CC 50 >20 μg/mL) [1], FtsZ-IN-4 exhibits promising potential for therapeutic applications.

L-I-OddU, a potent and selective anti-Epstein-Barr virus (EBV) agent, is a L-5'-halo-dioxolane nucleoside analogue. It demonstrates antiviral activity by effectively suppressing replicative EBV DNA and viral protein synthesis [1] [2]. With an EC 50 value of 0.03 μM, L-I-OddU exhibits high potency against EBV while maintaining low cytotoxicity, as indicated by its CC 50 value of 1000 nM.

CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a Kd of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC50 of 7.3 μM

Influenza virus-IN-1 (compound 14) exhibits anti-influenza A virus activities which is a potent inhibitor of influenza A virus with an CC 50 of >200 μM and EC 50 of 2.46 μM. Influenza virus-IN-1 exhibits a concentration dependent inhibition activity for PAN endonuclease (EC 50 = 312.36 nM) [1].